Belgian company Oxurion has finalized patient enrollment for the first part of a phase 2 diabetic macular edema study investigating a drug alternative to anti-VEGF therapy, the company announced in a press release.
The multicenter KALAHARI study is designed to evaluate the company’s leading drug candidate THR-149, a plasma kallikrein inhibitor, in patients who respond suboptimally to anti-VEGF therapy. Part A, which will enroll at least 18 patients, will determine the optimal dose to be used in part B.
“These data, if positive, will provide proof of concept and be (Read more...)